<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="167976">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00910728</url>
  </required_header>
  <id_info>
    <org_study_id>D1060C00001</org_study_id>
    <nct_id>NCT00910728</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases</brief_title>
  <official_title>A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York City Hoffman Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to test study drug AZD1480 to see how it may work to treat
      myeloproliferative diseases. The main purpose of this study is to determine the safety and
      tolerability of AZD1480. This is the first time the drug has been given to humans and is
      classed as a first time in man study. Its main purpose is to establish a safe dosage of the
      drug and provide additional information on any potential side effects this drug may cause.
      The study will also assess the blood levels and action of AZD1480 in the body over a period
      of time and will indicate whether the drug has a therapeutic effect on myeloproliferative
      diseases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General assessment of AEs, Pulmonary Function tests and chest CTScan.</measure>
    <time_frame>Screening, Day 1, Day 10, Day 22, Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic</measure>
    <time_frame>Day 1 (pre dose, 0.25hr, 0.5hr, 0.75hr, 1hr, 1.5hr, 2hr,3hr, 4hr, 6hr, 8hr, 12hr and 24hr); Day 28 (pre dose, 0.25hr, 0.5hr, 0.75hr, 1hr, 1.5hr,2hr, 3hr, 4hr, 6hr, 8hr, 12hr, 24hr)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>JAK2 Mutation Load</measure>
    <time_frame>Screening, then only for mutation + patients at the end of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory testing</measure>
    <time_frame>Screening, Day 1, Day 10, Day 22, and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of myelofibrosis - such as night sweats, fever, fatigue, itching, sweating</measure>
    <time_frame>Day 1, Day 2, Day 10, Day 22, Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Primary Myelofibrosis (PMF)</condition>
  <condition>Post-Polycythaemia Vera</condition>
  <condition>Essential Thrombocythaemia Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1480</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1480</intervention_name>
    <description>Oral capsule 2.5 mg, 10 mg and 40 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with myelofibrosis requiring therapy

          -  Evidence of post-menopausal status or sterile

          -  ECOG Performance Status &lt;/=2

        Exclusion Criteria:

          -  Prior therapy with any JAK2 medications

          -  Significant lung disorder or lung disease

          -  Previous radiation therapy to chest wall or chest infection requiring antibiotic
             treatment within 28 days before study screening

          -  Eye disease of the cornea

          -  Patients requiring oxygen supplementation

          -  Ejection fraction &lt;45% (ECHO/MUGA) or significant pulmonary hypertension &gt;40 mm Hg
             (by Echo/Doppler)

          -  Forced Expiratory Volume (FEV1)/Forced Vital Capacity (FVC) &lt;70% predicted or &gt;130%
             predicted

          -  Diffusing capacity of the Lung for Carbon Monoxide (DLCO) corrected for hemoglobin
             &lt;60% predicted, oxygen saturation &lt;88% at rest or after a 6-minute flat walk, without
             supplemental oxygen

          -  Chest infection requiring antibiotics within 7 days of the first dose of
             Investigational product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srdan Verstovsek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDACC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Hoffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mt. Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent Ribrag, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Becker Hewes, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 11, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Myelofibrosis (PMF)</keyword>
  <keyword>Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF)</keyword>
  <keyword>Myeloproliferative diseases</keyword>
  <keyword>Phase I</keyword>
  <keyword>Phase II</keyword>
  <keyword>Bone marrow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
